RecruitingNCT06508684

Current Status of BTKi Treatment for CLL/SLL in China

Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment

1,000 participants

Start Date

Jul 13, 2024

Study Type

OBSERVATIONAL

Conditions

CLL/SLL

Summary

BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This is an observational registry study in China collecting real-world data on patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have been treated with a class of targeted drugs called BTK inhibitors (such as ibrutinib or acalabrutinib). No experimental treatment is involved — researchers are just observing and documenting outcomes. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with CLL or SLL - You were treated with a BTK inhibitor between February 2023 and February 2024 **You may NOT be eligible if...** - You have a different type of lymphoma (not CLL/SLL) - The study investigators determine your case is unsuitable for inclusion Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.